Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments

Bibliography

• Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365(22):2110-21
   PubMed Web of Science ®Google Scholar
• Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201(5):703-11
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ, Madaio MP, Ni D, et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180(4):1295-306
   PubMed Web of Science ®Google Scholar
• Chan OT, Madaio MP, Shlomchik MJ. B cells are required for lupus nephritis in the polygenic, fas-intact MRL model of systemic autoimmunity. J Immunol 1999;163(7):3592-6
   PubMedGoogle Scholar
• Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998;160(1):51-9
   PubMed Web of Science ®Google Scholar
• Lech M, Weidenbusch M, Kulkarni OP, et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J Am Soc Nephrol 2011;22(8):1443-52
   PubMedGoogle Scholar
• Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189(10):1639-48
   PubMed Web of Science ®Google Scholar
• Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 2013;41:25-33
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Vital EM, Emery P. B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. Exp Rev Clin Immunol 2013;9(8):761-72
   PubMed Web of Science ®Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, et al. B cell antigen receptor signaling 101. Mol Immunol 2004;41(6-7):599-613
   PubMed Web of Science ®Google Scholar
• Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009;183(6):3561-7
   PubMedGoogle Scholar
• Liossis SN, Kovacs B, Dennis G, et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98(11):2549-57
   PubMed Web of Science ®Google Scholar
• Grammer AC, Fischer R, Lee O, et al. Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 2004;6(1):28
   Google Scholar
• Liu K, Mohan C. Altered B-cell signaling in lupus. Autoimmun Rev 2009;8(3):214-18
   PubMedGoogle Scholar
• Xu Y, Harder KW, Huntington ND, et al. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005;22(1):9-18
   PubMed Web of Science ®Google Scholar
• Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83(2):301-11
   PubMed Web of Science ®Google Scholar
• Hibbs ML, Harder KW, Armes J, et al. Sustained activation of lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med 2002;196(12):1593-604
   PubMed Web of Science ®Google Scholar
• Tsantikos E, Maxwell MJ, Kountouri N, et al. Genetic interdependence of lyn and negative regulators of B cell receptor signaling in autoimmune disease development. J Immunol 2012;189(4):1726-36
   PubMedGoogle Scholar
• Lu R, Vidal GS, Kelly JA, et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun 2009;10(5):397-403
   PubMed Web of Science ®Google Scholar
• Liossis S-NC, Solomou EE, Dimopoulos M-A, et al. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Invest Med 2001;49(2):157-65
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Kabouridis PS, Jury EC, et al. Decreased lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2005;52(12):3955-65
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong J, Mu R, et al. MicroRNA-30a promotes B cell hyperactivity in patients with systemic lupus erythematosus by direct interaction with lyn. Arthritis Rheum 2013;65(6):1603-11
   PubMedGoogle Scholar
• Lamagna C, Hu Y, Defranco AL, Lowell CA. B cell-specific loss of lyn kinase leads to autoimmunity. J Immunol 2014. [Epub ahead of print]
   Google Scholar
• Pamuk ON, Tsokos GC. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 2010;12(6):222
   PubMedGoogle Scholar
• Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998;101(7):1448
   PubMed Web of Science ®Google Scholar
• Krishnan S, Juang Y-T, Chowdhury B, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008;181(11):8145-52
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363(14):1303-12
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63(2):337-45
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58(11):3309-18
   PubMed Web of Science ®Google Scholar
• Liao C, Hsu J, Kim Y, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther 2013;15(5):R146
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN. TLRs and IFNs: critical pieces of the autoimmunity puzzle. J Clin Invest 2012;122(10):3464-6
   PubMedGoogle Scholar
• Bahjat FR, Pine PR, Reitsma A, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58(5):1433-44
   PubMed Web of Science ®Google Scholar
• Deng G-M, Liu L, Bahjat R, et al. Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice. Arthritis Rheum 2010;62(7):2086-92
   PubMed Web of Science ®Google Scholar
• Banham-Hall E, Clatworthy MR, Okkenhaug K. Suppl 2: the therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012;6:245
   PubMedGoogle Scholar
• Suarez-Fueyo A, Barber DF, Martinez-Ara J, et al. Enhanced phosphoinositide 3-kinase activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 2011;187(5):2376-85
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110 subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196(6):753-63
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297(5583):1031-4
   PubMed Web of Science ®Google Scholar
• Maxwell MJ, Tsantikos E, Kong AM, et al. Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J Autoimmun 2012;38(4):381-91
   PubMed Web of Science ®Google Scholar
• Barber DF, Bartolomé A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005;11(9):933-5
   PubMed Web of Science ®Google Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma Inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013;20(11):1364-74
   PubMed Web of Science ®Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012;120(24):4684-91
   PubMed Web of Science ®Google Scholar
• Mohamed AJ, Yu L, Bäckesjö C-M, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009;228(1):58-73
   PubMed Web of Science ®Google Scholar
• Smith CI, Baskin B, Humire-Greiff P, et al. Expression of bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 1994;152(2):557-65
   PubMed Web of Science ®Google Scholar
• Khan WN. Colonel bruton's kinase defined the molecular basis of x-linked agammaglobulinemia, the first primary immunodeficiency. J Immunol 2012;188(7):2933-5
   PubMedGoogle Scholar
• Aalipour A, Advani RH. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013;163(4):436-43
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJW, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 2012;119(16):3744-56
   PubMed Web of Science ®Google Scholar
• Steinberg BJ, Smathers PA, Frederiksen K, Steinberg AD. Ability of the xid gene to prevent autoimmunity in (NZB X NZW) F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J Clin Invest 1982;70(3):587
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci 2010;107(29):13075-80
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Vanarsa K, Bashmakov A, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther 2012;14(6):R243
   PubMed Web of Science ®Google Scholar
• Mina-Osorio P, LaStant J, Keirstead N, et al. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of bruton's tyrosine kinase: suppression of lupus nephritis by a selective inhibitor of BTK. Arthritis Rheum 2013;65(9):2380-91
   PubMed Web of Science ®Google Scholar
• Rankin AL, Seth N, Keegan S, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol 2013;191(9):4540-50
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62(1):222-33
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26
   PubMed Web of Science ®Google Scholar